Real-World Use of Letermovir and Maribavir for CMV Prophylaxis and Treatment in Solid Organ Transplant Recipients: Clinical Outcomes and Resistance Patterns From a Dual-Center Cohort
{{output}}
Background: Cytomegalovirus (CMV) is a major opportunistic infection in solid organ transplant (SOT) recipients. Although valganciclovir is first-line for CMV treatment, its use may be limited by resistance and myelotoxicity. Let... ...
